- HG-10-102-01
-
- $53.00 / 5mg
-
2026-04-21
- CAS:1351758-81-0
- Min. Order:
- Purity: 99.73%
- Supply Ability: 10g
|
| | [4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone Basic information |
| Product Name: | [4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone | | Synonyms: | [4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone;HG-10-102-01;(4-((5-chloro-4-
(methylamino)pyrimidin-2-yl)amino)-
3-
methoxyphenyl)(morpholino)methano
ne;LRRK2 INHIBITOR 1;CS-949;Methanone, [4-[[5-chloro-4-(methylamino)-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-morpholinyl-;Parkinson’s disease,Leucine-rich repeat kinase 2,inhibit,Ser910,BBB,HG 10 102 01,Radiosynthesis,Mouse embryonic fibroblast cells,Mouse Swiss 3T3 cells,MAP kinase interacting kinase,Ser935,MNK,Mitogen activated protein kinase interacting kinase,HG1010201,PET,Inhibitor,MAPK interacting kinase,HEK293 cells,LRRK2,Positron emission tomography;HG-10-102-01, 10 mM in DMSO | | CAS: | 1351758-81-0 | | MF: | C17H20ClN5O3 | | MW: | 377.83 | | EINECS: | | | Product Categories: | Amines, Aromatics, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals;Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;API | | Mol File: | 1351758-81-0.mol | ![[4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone Structure](CAS/GIF/1351758-81-0.gif) |
| | [4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone Chemical Properties |
| Boiling point | 641.1±65.0 °C(Predicted) | | density | 1.381±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | insoluble in H2O; ≥18.9 mg/mL in DMSO; ≥7.64 mg/mL in EtOH with ultrasonic | | form | solid | | pka | 4.60±0.10(Predicted) | | color | White to off-white |
| | [4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone Usage And Synthesis |
| Description | HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2; IC50 = 20.3 nM). It also inhibits the G2019S, A2016T, and [G2019S+A2016T] mutants of LRRK2 (IC50s = 3.2, 153, and 95.9 nM, respectively). HG-10-102-01 substantially inhibits Ser910 and Ser935 phosphorylation of both wild-type and G2019S mutant LRRK2 in cells. When given intraperitoneally, HG-10-102-01 penetrates the blood-brain barrier and inhibits phosphorylation of LRRK2 in the brain as well as the kidney and spleen. | | Uses | [4-[[5-Chloro-4-(methylamino)-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-morpholinylmethanone is an aminopyrimidine derivative as LRRK2 modulators used for the treatment of Parkinson''s disease. | | Definition | ChEBI: HG-10-102-01 is a monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 4-{[5-chloro-4-(methylamino)pyrimidin-2-yl]amino}-3-methoxybenzoic acid with the amino group of morpholine. It is an inhibitor of leucine-rich repeat kinase 2 (LRRK2). It has a role as an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor. It is an aminopyrimidine, a member of morpholines, a monocarboxylic acid amide, an organochlorine compound, a secondary amino compound and an aromatic ether. | | in vivo | HG-10-102-01 (0-100 mg/kg, IP, once) shows inhibition of LRRK2 Ser910/Ser935 phosphorylation in kidney, spleen, and brain of mice[1].
HG-10-102-01 (1 mg/kg, IV; 10 mg/kg, PO; once) shows good oral bioavailability (%F = 67), a short half-life of 0.13 h, and low plasma exposure[1]. | Animal Model: | Wild type male C57BL/6 mice[1] | | Dosage: | 0, 3, 10, 30, 50, and 100 mg/kg | | Administration: | IP, once | | Result: | Showed near complete dephosphorylation of Ser910 and Ser935 of LRRK2 in all tissues including brain at 100 mg/kg and 50 mg/kg, but only partial inhibition in brain at the 30 and 10 mg/kg doses. |
| Animal Model: | Wild type male C57BL/6 mice[1] | | Dosage: | 1 mg/kg (IV); 10 mg/kg (PO) | | Administration: | IV, PO; once (Pharmacokinetic Analysis) | | Result: | Pharmacokinetic Parameters of HG-10-102-01 in male C57BL/6 mice[1].
| IV (1 mg/kg) | PO (10 mg/kg) | | Tmax (h) | | 0.25 | | Cmax (ng/mL) | 1330 | 1241 | | AUClast (ng/mLh) | 74.85 | 502.34 | | AUCINF (ng/mLh) | 75.06 | 503.41 | | T1/2 (h) | 0.13 | | | CL (mL/min/kg) | 222.04 | | | Vss (L/kg) | 1.68 | | | F (%) | | 67 |
|
| | references | [1] choi hg1, zhang j, deng x, hatcher jm, patricelli mp, zhao z, alessi dr, gray ns. brain penetrant lrrk2 inhibitor. acs med chem lett. 2012 aug 9;3(8):658-662. epub 2012 jun 18. |
| | [4-[[5-Chloro-4-(MethylaMino)-2-pyriMidinyl]aMino]-3-Methoxyphenyl]-4-MorpholinylMethanone Preparation Products And Raw materials |
|